Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 2010

View Archived Issues

AstraZeneca discloses novel FGFR inhibitors

Enhanced-sensitivity Trofile assay and HIV V3-loop sequencing comparably predict maraviroc response

FDA approves new labeling of Xylocaine including updated safety information

Prosidion claims new glucose-dependent insulinotropic receptor agonists

Efficacy and safety results of ecallantide treatment for hereditary angioedema attacks

Phase III study supports once-daily dosing of darunavir/ritonavir in HIV-1 infection

Genentech identifies novel MEK inhibitors

Hyperactivity models differentiate SSR-103800 from other antipsychotics

Orchid Research Laboratories presents new PDE4 inhibitor OCI-2987

New voltage-gated sodium channel inhibitors described by Vertex

UCB presents novel PI3K inhibitors

Novartis and Ono submit manufacturing and marketing application in Japan for rivastigmine

COMP grants perifosine positive opinion as orphan medicinal product in MM

Welichem Biotech begins enrollment in phase IIa WBI-1001 trial in psoriasis

FDA accepts for filing VIVUS' Qnexa NDA for obesity

Shionogi provides update on its developments in Q3 of 2009

Ariad's AP-24534 receives orphan drug status for CML

Watson Pharmaceuticals licenses Population Council's novel contraceptive ring

Quark Pharmaceuticals begins dosing in phase I trial of QPI-1007 for NAION

Janssen submits NDA for R-113675 in Japan for AD

Merck KGaA to acquire Millipore

GTC Biotherapeutics provides update on TG-20 MAb

FDA requests Vion conduct phase II trial of Onrigin in AML prior to phase III study

Acorda Therapeutics' Ampyra launched in U.S. and Puerto Rico

Icagen reports phase Ib results on ICA-105665 in pain

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...